Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting ama1 class I epitopes

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Sedegah, Martha ^a   Hollingdale, Michael R ^a   Farooq, Fouzia ^a   Ganeshan, Harini ^a   Belmonte, Maria ^a   Kim, Yohan ^b   Peters, Bjoern ^b   Sette, Alessandro ^b   Huang, Jun ^a   McGrath, Shannon ^a   Abot, Esteban ^a   Limbach, Keith ^a   Shi, Meng ^c   Soisson, Lorraine ^d   Diggs, Carter ^d   Chuang, Ilin ^a   Tamminga, Cindy ^a   Epstein, Judith E ^a   Villasante, Eileen ^a   Richie, Thomas L ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d Office of HIV/AIDS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APICAL MEMBRANE ANTIGEN 1; DNA VACCINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; DNA; MALARIA VACCINE; MEMBRANE PROTEIN; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNITY; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; MALARIA FALCIPARUM; PERIPHERAL BLOOD MONONUCLEAR CELL; ADENOVIRIDAE; ADULT; CLINICAL TRIAL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PARASITOLOGY; PATHOGENICITY; PATHOLOGY; PLASMODIUM FALCIPARUM;

HUMAN ADENOVIRUS TYPE 5; PLASMODIUM FALCIPARUM;

ADENOVIRIDAE; ADULT; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; DNA; EPITOPES; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-2; MALARIA VACCINES; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907484025     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106241     Document Type: Article

References (63)

1. Murray CJ, Rosenfeld LG, Lim SS, Andrews KG, Foreman KJ, et al. (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413-431.
2. Das P, Horton R (2010) Malaria elimination: worthy, challenging, and just possible. Lancet 376: 1515-1517.
3. Weiss WR, Good MF, Hollingdale MR, Miller LH, Berzofsky JA (1989) Genetic control of immunity to Plasmodium yoelii sporozoites. J Immunol 143: 4263-4266.
4. Hoffman SL, Weiss W, Mellouk S, Sedegah M (1990) Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes. Immunol Lett 25: 33-38.
5. Weiss WR, Jiang CG (2012) Protective CD8+ T lymphocytes in primate: immunized with malaria sporozoites. PLoS One 7: e31247.
6. Overstreet MG, Cockburn IA, Chen YG, Zavala F (2008) Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol Rev 225: 272-283.
7. Krzych U, Dalai S, Zarling S, Pichugin A (2012) Memory CD8 T cells specific for plasmodia liver-stage antigens maintain protracted protection against malaria. Front Immunol 3: 370.
8. Doolan DL, Martinez-Alier N (2006) Immune response to pre-erythrocytic stages of malaria parasites. Curr Mol Med 6: 169-185.
9. Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, et al. (2011) Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9: 451-462.
10. Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, et al. (2002) Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20: 1039-1045.
11. Sedegah M, Hedstrom R, Hobart P, Hoffman SL (1994) Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Nad Acad Sci USA 91: 9866-9870.
12. Jiang G, Shi M, Conteh S, Richie N, Banania G, et al. (2009) Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS One 4: e6559.
13. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, et al. (2004) A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA METRAP against malaria infection in Gambian adults. PLoS Med 1: e33.
14. Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, et al. (2006) Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 24: 4709-4715.
15. Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, et al. (2011) A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 29: 7514-7522.
16. Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, et al. (2012) Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. PLoS One 7: e31208.
17. Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, et al. (2013) Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA METRAP, in healthy Gambian and Kenyan adults. PLoS One 8: e57726.
18. Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, et al. (2005) Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 102: 4836-4841.
19. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, et al. (2013) DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity PLoS One 8: 1371.
20. Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, et al. (2013) Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4: 2836.
21. Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, et al. (2004) A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 279: 9490-9496.
22. Nussenzweig V, Nussenzweig RS (1985) Circumsporozoite proteins of malaria parasites. Cell 42: 401-403.
23. Lumsden JM, Schwenk RJ, Rein LE, Moris P, Janssens M, et al. (2011) Protective immunity induced with the RTS, S/AS vaccine is associated with IL-2 and TNF-alpha producing effector and central memory CD4 T cells. PLoS One 6: e20775.
24. Policy SD, Mwangi T, Koeken GH, Thomas AW, Dutta S, et al. (2004) Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718-728.
25. Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, et al. (2011) Adenovirus 5-vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults. PLoS One 6: e24586.
26. Tamminga C, Sedegah M, Maiolatesi S, Fedders C, Reyes S, et al. (2013) Human Adenovirus 5-Vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA Vaccine encoding CSP and AMA1 is safe, well tolerated and immunogenic but does not protect against controlled human malaria infection. Hum Vaccin Immunother 9: 2165-2177.
27. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
28. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, et al. (2011) Live Attenuated Malaria Vaccine Designed to Protect through Hepatic CD8+ T Cell Immunity. Science.
29. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, et al. (2013) Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 1359-1365.
30. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Jr., et al. (2007) A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS, S/AS02A in malaria-naive adults. Vaccine 25: 5359-5366.
31. Wang R, Epstein J, Baraceros FM, Gorak EJ, Charoenvit Y, et al. (2001) Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 98: 10817-10822.
32. Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, et al. (2011) Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMAL Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 6: e25868.
33. Sedegah M, Kim D, Ganeshan H, Huang J, Belmonte M, et al. (2013) Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP). Malar J 12: 185.
34. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, et al. (1997) Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 186: 1407-1418.
35. Vasconcelos JR, Dominguez MR, Araujo AF, Ersching J, Tararam CA, et al. (2012) Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination. Front Immunol 3: 358.
36. Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, et al. (2009) Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 25: 103 -114.
37. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, et al. (2010) Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78: 145-153.
38. Wherry EJ (2009) T cell exhaustion. Nat Immunol 12: 492-499.
39. Lundegaard C, Lund O, Nielsen M (2008) Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 24: 1397-1398.
40. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immu no genetics 50: 213-219.
41. Sidney J, Peters B, Frahm N, Brander C, Sette A (2008) HLA class I supertypes: a revised and updated classification. BMC Immunol 9: 1.
42. Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, et al. (2006) A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombos-pondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 74: 5933-5942.
43. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, et al. (2008) Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46: 1769-1781.
44. Miao J, Li X, Liu Z, Xue C, Bujard H, et al. (2006) Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMAl)-based DNA, protein and recombinant modified vaccinia Ankara vaccines. Vaccine 24: 6187-6198.
45. Bouillet LE, Dias MO, Dorigo NA, Moura AD, Russell B, et al. (2011) Longterm humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol. Infect Immun 79: 3642-3652.
46. Steffensen MA, Holst PJ, Steengaard SS, Jensen BA, Bartholdy C, et al. (2013) Qualitative and quantitative analysis of adenovirus type 5 vector-induced memory CD8 T cells: not as bad as their reputation. J Virol 87: 6283-6295.
47. De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, et al. (2011) HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol 187: 3391-3401.
48. Kirman JR, Seder RA (2003) DNA vaccination: the answer to stable, protective T-cell memory? Curr Opin Immunol 15: 471-476.
49. Schmidt NW, Podyminogin RL, Buder NS, Badovinac VP, Tucker BJ, et al. (2008) Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Nad Acad Sci USA 105: 14017 -14022.
50. Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, et al. (2013) Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol 190: 2720-2735.
51. Yang SH, Lee CG, Park SH, Im SJ, Kim YM, et al. (2006) Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 13: 1110 -1117.
52. Penaloza-MacMaster P, Provine NM, Ra J, Borducchi EN, McNally A, et al. (2013) Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol 87: 1373-1384.
53. Tan WG, Jin HT, West EE, Penaloza-MacMaster P, Wieland A, et al. (2013) Comparative analysis of simian immu no deficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J Virol 87: 1359-1372.
54. Todryk SM, Pathan AA, Keating S, Porter DW, Berthoud T, et al. (2009) The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology 128: 83-91.
55. Huaman MG, Mullen GE, Long CA, Mahanty S (2009) Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells. Vaccine 27: 5239-5246.
56. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, et al. (2005) Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 174: 449-455.
57. Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, et al. (2011) CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria. J Immunol 187: 1347-1357.
58. Tse SW, Cockburn IA, Zhang H, Scott AL, Zavala F (2013) Unique transcriptional profile of liver-resident memory CD8+ T cells induced by immunization with malaria sporozoites. Genes Immun 14: 302-309.
59. Cockburn IA, Chakravarty S, Overstreet MG, Garcia-Sastre A, Zavala F (2008) Memory CD8+ T cell responses expand when antigen presentation overcomes T cell self-regulation. J Immunol 180: 64-71.
60. Hafalla JC, Morrot A, Sano G, Milon G, Lafaille JJ, et al. (2003) Early selfregulatory mechanisms control the magnitude of CD8+ T cell responses against liver stages of murine malaria. J Immunol 171: 964-970.
61. Remarque EJ, Faber BW, Koeken GH, Thomas AW (2008) Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24: 74-84.
62. Sedegah M, Kim Y, Peters B, McGrath S, Ganeshan H, et al. (2011) Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein. Malar J 9: 241.
63. Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, et al. (2011) Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med 17: 989-995.